Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-04-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/2042018814543483 |
| _version_ | 1818280783378382848 |
|---|---|
| author | Marwa R. Al-Badri Sami T. Azar |
| author_facet | Marwa R. Al-Badri Sami T. Azar |
| author_sort | Marwa R. Al-Badri |
| collection | DOAJ |
| description | Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis. |
| first_indexed | 2024-12-12T23:54:43Z |
| format | Article |
| id | doaj.art-305bd73ba5b9480986a75d3743d464cc |
| institution | Directory Open Access Journal |
| issn | 2042-0188 2042-0196 |
| language | English |
| last_indexed | 2024-12-12T23:54:43Z |
| publishDate | 2014-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Endocrinology and Metabolism |
| spelling | doaj.art-305bd73ba5b9480986a75d3743d464cc2022-12-22T00:06:36ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01882042-01962014-04-01510.1177/2042018814543483Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasisMarwa R. Al-BadriSami T. AzarGlucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis.https://doi.org/10.1177/2042018814543483 |
| spellingShingle | Marwa R. Al-Badri Sami T. Azar Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis Therapeutic Advances in Endocrinology and Metabolism |
| title | Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis |
| title_full | Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis |
| title_fullStr | Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis |
| title_full_unstemmed | Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis |
| title_short | Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis |
| title_sort | effect of glucagon like peptide 1 receptor agonists in patients with psoriasis |
| url | https://doi.org/10.1177/2042018814543483 |
| work_keys_str_mv | AT marwaralbadri effectofglucagonlikepeptide1receptoragonistsinpatientswithpsoriasis AT samitazar effectofglucagonlikepeptide1receptoragonistsinpatientswithpsoriasis |